Solésence Swings to $0.8M Net Loss in Q1 as Revenue Declines
SLSN sits 73% above its 52-week low of $0.78 on elevated volume (3.1× avg).
Summary
Solésence reported its first quarter 2026 financial results, revealing a significant swing to a net loss of $0.8 million, compared to a net income of $0.08 million in the prior year period. Revenue also declined to $13.0 million from $14.6 million year-over-year, despite an improvement in gross margin to 26%. This report provides new, material financial data following the company's last annual filing. The substantial decline in profitability and revenue indicates operational challenges that could negatively impact investor sentiment and the stock price. Traders will be closely monitoring the upcoming conference call for further insights into the company's strategic initiatives and outlook for reversing these trends.
At the time of this announcement, SLSN was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $105.9M. The 52-week trading range was $0.78 to $5.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.